Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

(2022) Ruth M. de Tute et al.   JOURNAL OF CLINICAL ONCOLOGY

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

(2022) Ajay K. Nooka et al.   Blood Cancer Journal

The emerging therapeutic landscape of relapsed/refractory multiple myeloma

(2022) Benjamin Tanenbaum et al.   ANNALS OF HEMATOLOGY

Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE

(2021) Jesus F. San-Miguel et al.   BLOOD

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: a randomised phase 2 trial by the Nordic Myeloma Study Group

(2021) Henrik Gregersen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

(2020) Nikhil C. Munshi et al.   Blood Advances

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

(2018) Aurore Perrot et al.   BLOOD

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

(2018) Graham H Jackson et al.   LANCET ONCOLOGY

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

(2017) Philip L. McCarthy et al.   JOURNAL OF CLINICAL ONCOLOGY

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

(2017) J Flores-Montero et al.   LEUKEMIA

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

(2015) Sergio Giralt et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

(2015) Maria Arroz et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21

(2015) Hareth Nahi et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

(2015) Francesca Gay et al.   LANCET ONCOLOGY

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

(2014) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

(2008) B. Barlogie et al.   BLOOD